IRIS
CANONICA, Giorgio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.091
EU - Europa 3.393
AS - Asia 1.950
AF - Africa 609
SA - Sud America 36
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 13
Totale 19.112
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.905
SG - Singapore 1.134
FI - Finlandia 966
IE - Irlanda 830
NG - Nigeria 596
FR - Francia 412
CN - Cina 403
DE - Germania 326
NL - Olanda 255
GB - Regno Unito 192
CA - Canada 179
TR - Turchia 175
IT - Italia 117
SE - Svezia 98
IL - Israele 79
RU - Federazione Russa 70
IN - India 42
BR - Brasile 26
BE - Belgio 25
ES - Italia 18
AU - Australia 16
CZ - Repubblica Ceca 16
HK - Hong Kong 14
IR - Iran 14
JP - Giappone 13
UA - Ucraina 13
AT - Austria 11
KR - Corea 11
ID - Indonesia 9
IQ - Iraq 9
RO - Romania 9
A2 - ???statistics.table.value.countryCode.A2??? 8
CL - Cile 8
EG - Egitto 7
SA - Arabia Saudita 7
GR - Grecia 6
MX - Messico 6
PL - Polonia 6
GE - Georgia 5
NO - Norvegia 5
NP - Nepal 5
BD - Bangladesh 4
CH - Svizzera 4
DK - Danimarca 4
EU - Europa 4
MN - Mongolia 4
NZ - Nuova Zelanda 4
PK - Pakistan 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
MD - Moldavia 3
PH - Filippine 3
PT - Portogallo 3
TW - Taiwan 3
AR - Argentina 2
BG - Bulgaria 2
LB - Libano 2
ZA - Sudafrica 2
AL - Albania 1
AO - Angola 1
AP - ???statistics.table.value.countryCode.AP??? 1
BF - Burkina Faso 1
HU - Ungheria 1
JO - Giordania 1
KG - Kirghizistan 1
MA - Marocco 1
OM - Oman 1
PA - Panama 1
UG - Uganda 1
Totale 19.112
Salva come PNG Salva come JPEG
Città #
Wilmington 4.540
San Mateo 1.699
Ann Arbor 1.032
Helsinki 965
Leawood 869
Dublin 828
Lawrence 773
Princeton 773
Singapore 709
Benin City 596
Fairfield 577
Woodbridge 513
Chandler 488
Paris 391
Shanghai 347
Amsterdam 236
Kocaeli 169
London 166
Toronto 160
Boardman 109
New York 106
Ashburn 103
Norwalk 96
Santa Clara 66
Monmouth Junction 43
Falkenstein 32
Moscow 31
Seattle 31
Phoenix 28
Des Moines 24
Brussels 20
Milan 20
Beijing 19
Los Angeles 19
Redmond 18
Redwood City 18
San Diego 18
Cambridge 14
Clearwater 14
Abbiategrasso 12
Andover 12
Calgary 10
Falls Church 10
Brno 9
Frankfurt am Main 9
Hanover 9
Houston 8
Jakarta 8
Meppel 8
Augusta 7
Munich 7
Pune 7
Rome 7
Kemerovo 6
Bengaluru 5
Istanbul 5
Jaipur 5
Jumet 5
Kathmandu 5
Madrid 5
Prague 5
Sydney 5
São Paulo 5
Baghdad 4
Bangkok 4
Berlin 4
Buffalo 4
Council Bluffs 4
Duncan 4
Fremont 4
Harbin 4
Hong Kong 4
Krakow 4
Lutz 4
Mumbai 4
Nanjing 4
Newark 4
Pescia 4
St Petersburg 4
Winnipeg 4
Cairo 3
Castel Maggiore 3
Chisinau 3
Dornbirn 3
Gallarate 3
Gothenburg 3
Las Vegas 3
Leipzig 3
Novokuznetsk 3
Philadelphia 3
Porto 3
Rio De Janeiro 3
Riyadh 3
Sacramento 3
Saint Louis 3
Saint Paul 3
Scranton 3
Taiyuan 3
Tampa 3
Tokyo 3
Totale 16.962
Salva come PNG Salva come JPEG
Nome #
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco 96
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry 89
A critical appraisal on AIT in childhood asthma. 87
Very rapid improvement of extended nitric oxide parameters, associated with clinical and functional betterment, in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) treated with Dupilumab 74
Effects on symptoms and quality of life of hypertonic saline nasal spray added to antihistamine in persistent allergic rhinitis--a randomized controlled study 74
Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. 73
An academic allergy unit during COVID-19 pandemic in Italy. 71
Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients. 68
A Charter to Improve Patient Care in Severe Asthma 62
Evolving phenotypes to endotypes: is precision medicine achievable in asthma? 58
Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment 56
Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps 56
30 Years Of Sublingual Immunotherapy 56
60Co therapy as an "allergic breakthrough" in a case of food allergy 55
Aligning the Good Practice MASK With the Objectives of the European Innovation Partnership on Active and Healthy Ageing 54
Microarray Immunodiagnostics for Aeroallergens 53
2019 ARIA Care pathways for allergen immunotherapy 53
Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity 52
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis 52
The Severe Asthma Network in Italy: Findings and Perspectives 51
Strategies to reduce corticosteroid-related adverse events in asthma 51
Real-life studies of biologics used in asthma patients: key differences and similarities to trials 50
A 4-year trial of tiotropium in chronic obstructive pulmonary disease 50
A multi-allergen ELISA screening method. Comparison with Pharmacia CAP system and Phazet skin prick test 50
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects 49
Treatable traits in chronic rhinosinusitis with nasal polyps 48
A multicentric study on sensitivity and specificity of a new in vitro test for measurement of IgE antibodies 47
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 47
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress 47
A survey of the burden of allergic rhinitis in Europe 47
Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients 46
Appropriateness in allergic respiratory diseases health care in Italy: definitions and organizational aspects 45
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL) 45
Pharmacoeconomic evaluation of oral corticosteroid adverse events in patients with severe asthma 45
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy 45
Current insights in allergen immunotherapy. 44
Inhaled corticosteroids safety and adverse effects in patients with asthma 44
Asthma: personalized and precision medicine 44
A model of allergen-driven human airway contraction:beta2 pathway dysfunction without cytokine involvement 44
Choosing wisely in Allergology: a Slow Medicine approach to the discipline promoted by the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) 44
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 43
A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire 43
Diagnosis and management of moderate to severe adult atopic dermatitis: a Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), and the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA) 42
A review of the use of fluticasone furoate since its launch 42
EAACI guidelines on allergen immunotherapy: Executive statement 42
Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions 42
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials 42
EUFOREA consensus on biologics for CRSwNP with or without asthma 41
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients 41
Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study 41
GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe 41
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis 41
New drugs in early-stage clinical trials for allergic rhinitis 40
GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic' 40
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis 40
[GA(2)LEN (Global Allergy and Asthma European Network): European network of excellence for asthma and allergic diseases] 40
La diagnostica delle malattie autoimmuni 40
Escaping the trap of allergic rhinitis. 39
EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria 39
The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update 39
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper 38
Ketotifen treatment of adverse reactions to foods: clinical and immunological effects 38
Characteristics and treatment regimens across ERS SHARP severe asthma registries. 37
The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update 37
GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe 37
Year in review: Allergen immunotherapy 37
[Our experience in the treatment of bronchial asthma and asthmatic bronchitis with salbutamol] 37
T cell activation surface markers and autologous mixed lymphocyte reaction do not differ in true and pseudo food allergy 36
Suppressor activity of T cells bearing Fc-receptors for IgG on lymphoid colony formation 36
Performance evaluation of ImmunoCAP® ISAC 112: a multi-site study 36
[ICAM-1 and allergic inflammation] 36
Clinical outcomes related to molecular allergy diagnosis 35
Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. 35
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy 35
Wellbeing, illness perception and coping strategies in Italian celiac patients 35
T cell activation through different membrane structures (T3/Ti, T11, T44) and frequency analysis of proliferating and interleukin-2 producer T lymphocyte precursors in aged individuals 35
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria 34
Erratum to: Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5)(Clin Transl Allergy (2016) 6 (29) DOI: 10.1186/s13601-016-0116-9) 34
The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials. 33
Subpopulation of human T lymphocytes, functional characteristics 33
Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA plus LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study 33
EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria 33
Abnormalities of circulating T cell subsets in atopy: influence of specific immunotherapy 33
T-lymphocyte activation and allergy 33
Pilot study of mobile phone technology in allergic rhinitis in European countries: The MASK-rhinitis study 33
EAACI/GA(2)LEN/EDF/WAO - Guideline for the Definition, Classification, Diagnosis and Management of Urticaria - Consensus, German Translation Guideline of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF) and the World Allergy Organization (WAO) 33
The adhesion molecules of allergic inflammation: recent insights into their functional roles 32
Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone 32
Cutting Edge: Biomarkers for Chronic Spontaneous Urticaria. 31
World Allergy Organization-McMaster University Guidelines for Allergic Disease Prevention (GLAD-P): Prebiotics 31
Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study 31
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs 31
Imbalance of circulating T lymphocytes subsets in allergic ophtalmorhinitis 31
Atopic asthma: evaluation of T-cell activation by means of 4F2 monoclonal antibody 31
Comparison of the colony forming capacities of human T lymphocyte subpopulations 31
What do we need to learn to optimize the SLIT alternative? 31
Galectin-3: An early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months 31
Imbalances of T cell subpopulations in patients with atopic diseases and effect of specific immunotherapy 31
Assessing biomarkers in a real-world severe asthma study (ARIETTA) 31
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation 31
Totale 4.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 224.938
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 224.938
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020767 0 0 0 0 0 0 0 0 0 0 0 767
2020/20218.207 11 32 11 12 18 2.500 1.316 572 2.071 696 14 954
2021/20223.078 117 7 51 783 15 17 131 612 304 295 682 64
2022/20234.270 1.621 85 827 139 101 86 19 93 282 776 219 22
2023/20243.405 169 387 772 31 32 141 119 117 51 34 640 912
2024/2025324 79 34 38 53 56 64 0 0 0 0 0 0
Totale 20.051